IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0261077.html
   My bibliography  Save this article

Drug company payments to General Practices in England: Cross-sectional and social network analysis

Author

Listed:
  • Eszter Saghy
  • Shai Mulinari
  • Piotr Ozieranski

Abstract

Although there has been extensive research on pharmaceutical industry payments to healthcare professionals, healthcare organisations with key roles in health systems have received little attention. We seek to contribute to addressing this gap in research by examining drug company payments to General Practices in England in 2015. We combine a publicly available payments database managed by the pharmaceutical industry with datasets covering key practice characteristics. We find that practices were an important target of company payments, receiving £2,726,018, equivalent to 6.5% of the value of payments to all healthcare organisations in England. Payments to practices were highly concentrated and specific companies were also highly dominant. The top 10 donors and the top 10 recipients amassed 87.9% and 13.6% of the value of payments, respectively. Practices with more patients, a greater proportion of elderly patients, and those in more affluent areas received significantly more payments on average. However, the patterns of payments were similar across England’s regions. We also found that company networks–established by making payments to the same practices–were largely dominated by a single company, which was also by far the biggest donor. Greater policy attention is required to the risk of financial dependency and conflicts of interests that might arise from payments to practices and to organisational conflicts of interests more broadly. Our research also demonstrates that the comprehensiveness and quality of payment data disclosed via industry self-regulatory arrangements needs improvement. More interconnectivity between payment data and other datasets is needed to capture company marketing strategies systematically.

Suggested Citation

  • Eszter Saghy & Shai Mulinari & Piotr Ozieranski, 2021. "Drug company payments to General Practices in England: Cross-sectional and social network analysis," PLOS ONE, Public Library of Science, vol. 16(12), pages 1-16, December.
  • Handle: RePEc:plo:pone00:0261077
    DOI: 10.1371/journal.pone.0261077
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261077
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0261077&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0261077?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jorge Mejia & Amanda Mejia & Franco Pestilli, 2019. "Open data on industry payments to healthcare providers reveal potential hidden costs to the public," Nature Communications, Nature, vol. 10(1), pages 1-8, December.
    2. Rickard, Emily & Ozieranski, Piotr & Mulinari, Shai, 2019. "Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK," Health Policy, Elsevier, vol. 123(12), pages 1244-1250.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Moriarty, Frank & Larkin, James & Fahey, Tom, 2021. "Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study," Health Policy, Elsevier, vol. 125(10), pages 1297-1304.
    2. Mulinari, Shai & Martinon, Luc & Jachiet, Pierre-Alain & Ozieranski, Piotr, 2021. "Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries," Health Policy, Elsevier, vol. 125(7), pages 915-922.
    3. Eisenkraft Klein, Daniel, 2023. "Profit and Prudence: Navigating Psychedelic Commercialization Through Lessons from the Prescription Opioid Crisis," Health Policy, Elsevier, vol. 138(C).
    4. Ansari, Bahareh, 2021. "Industry payments and physicians prescriptions: Effect of a payment restriction policy," Social Science & Medicine, Elsevier, vol. 278(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0261077. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.